IDEAYA Biosciences, Inc.
IDYA$2.70B
Mid CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSOUTH SAN FRANCISCO131 employees
Drugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
4
Next Catalyst
Dec 31, 2026
35wMarket Overview
Stock performance and key metrics
IDYA News
Catalyst Timeline
4 upcoming, 1 past
Drug Pipeline
Crizotinib
Metastatic Uveal Melanoma
Darovasertib
Uveal Melanoma
IDE196
Metastatic Uveal Melanoma
IDE849
Small-cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Crizotinib | Phase 3 | Metastatic Uveal Melanoma | - | - |
Darovasertib | Phase 3 | Uveal Melanoma | - | - |
IDE196 | Phase 3 | Metastatic Uveal Melanoma | - | - |
IDE849 | Phase 2 | Small-cell Lung Cancer | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply